In 2001, a group investigated the invasive activity by one 17-mer phosphorothioate ASOs targeting KRAS point mutations in MIA PaCa-2, PANC-1, and BxPC-3 pancreatic cancer cells, and the results indicated that 17-mer ASOs could strongly inhibit the invasive activity of MIA PaCa-2, PANC-1 with aggressively mutated KRAS but not in BxPC-3 with a wild-type KRAS (Nakada et al., 2001). Here, KRAS is linked to pancreatic neoplasm.